trending Market Intelligence /marketintelligence/en/news-insights/trending/rmos1i96p5mrazjiwubryw2 content esgSubNav
In This List

Tenax Therapeutics implements 1-for-20 reverse stock split

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Tenax Therapeutics implements 1-for-20 reverse stock split

Tenax Therapeutics Inc. implemented a 1-for-20 reverse split of its common shares to regain compliance with the Nasdaq Capital Market's minimum $1 bid price listing rule.

The Morrisville, N.C.-based specialty pharmaceutical's common stock will trade on a split-adjusted basis starting Feb. 26.

The split will reduce Tenax's outstanding common shares to about 1.4 million from 28.2 million.

Tenax noted that there is no assurance that the split will increase its bid price. The company has until March 12 to regain compliance with Nasdaq's listing requirements.